Douglass Winthrop Advisors LLC decreased its stake in Celgene Co. (NASDAQ:CELG) by 4.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,198 shares of the biopharmaceutical company’s stock after selling 340 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Celgene were worth $461,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the company. Sippican Capital Advisors acquired a new stake in shares of Celgene in the fourth quarter worth approximately $318,000. Virtu Financial LLC boosted its holdings in shares of Celgene by 337.5% during the fourth quarter. Virtu Financial LLC now owns 52,495 shares of the biopharmaceutical company’s stock valued at $3,364,000 after acquiring an additional 40,497 shares during the period. Daiwa SB Investments Ltd. raised its stake in shares of Celgene by 9.1% during the fourth quarter. Daiwa SB Investments Ltd. now owns 15,550 shares of the biopharmaceutical company’s stock valued at $997,000 after purchasing an additional 1,300 shares in the last quarter. Prentiss Smith & Co. Inc. raised its stake in shares of Celgene by 13.7% during the fourth quarter. Prentiss Smith & Co. Inc. now owns 9,256 shares of the biopharmaceutical company’s stock valued at $593,000 after purchasing an additional 1,112 shares in the last quarter. Finally, BKD Wealth Advisors LLC raised its position in Celgene by 18.6% in the fourth quarter. BKD Wealth Advisors LLC now owns 4,188 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 658 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.
CELG has been the subject of several recent research reports. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a research note on Thursday, October 25th. reiterated a “buy” rating on shares of Celgene in a report on Monday, December 3rd. Mizuho set a $117.00 target price on Celgene and gave the company a “buy” rating in a research note on Tuesday, October 30th. UBS Group set a $94.00 target price on Celgene and gave the company a “buy” rating in a research note on Saturday, October 27th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $100.00 target price on shares of Celgene in a research note on Thursday, January 3rd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $110.47.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. As a group, equities analysts predict that Celgene Co. will post 7.45 EPS for the current year.
WARNING: This report was first posted by BBNS and is owned by of BBNS. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://baseballnewssource.com/2019/01/19/douglass-winthrop-advisors-llc-sells-340-shares-of-celgene-co-celg/3151808.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: Index Funds
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.